Results 171 to 180 of about 1,454,174 (267)

The efficacy of preoperative evolocumab-rosuvastatin combination therapy in patients with ST-elevation myocardial infarction. [PDF]

PLoS One
Li H, Dong H, Bao S, Wang X, Fu Z.
europepmc   +1 more source

How to improve the effectiveness of combination therapy of arterial hypertension in patients with concomitant chronic obstructive pulmonary disease?

, 2020
N. Yu. Grigorieva, M. O. Samolyuk, T. V. Sheshina, N. B. Koroleva, Koroleva Tv   +4 more
openalex   +1 more source

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Effectiveness of cryofiltration and mizoribine combination with oral steroid therapy in a patient with membranoproliferative glomerulonephritis due to essential cryoglobulinemia [PDF]

, 2019
Yuka Kurokawa, Kiyomi Koike, Yusuke Kaida, Sakuya Ito, Hirotane Chiba, Kengo Urae, Tomofumi Moriyama, Nao Nakamura, T Imai, Ryo Shibata, Takuma Hazama, Daisuke Wakasugi, Seiya Okuda, Kei Fukami   +13 more
openalex   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Advances in the Clinical Application of MAC: A Review of Drug Selection, Combination Therapy, and Administration Methods. [PDF]

Drug Des Devel Ther
Lei XH, Yang WW, Luo X, Rao PG, Guo R.
europepmc   +1 more source

Safety of Advanced Combination Treatment With Selective JAK1 Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience [PDF]

C. Cussac, Pauline Rivière, Romain Altwegg, Ludovic Caillo, Florian Poullenot, David Laharie, Cyrielle Gilletta, Guillaume Le Cosquer   +7 more
openalex   +1 more source

Antibiotic Tolerance and Combination Therapy

mBio, 2015
David C. Bean, Sarah M. Wigmore
doaj   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Atezolizumab Plus Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma: An Institutional Experience. [PDF]

Biomedicines
Esmail A, Hamadneh Y, Khasawneh B, Al-Rawi M, Al-Najjar E, Dhillon V, Alhaj A, Rayyan Y, Abdelrahim M.   +8 more
europepmc   +1 more source